MagnaniJLSteplewsliZKoprowskiHGinsburgV. Identification of the gastrointestinal and pancreatic cancer associated antigen detected by monoclonal antibody 19-9 in the sera of the patients as a mucin. Cancer Res1983; 43: 5489–92.
2.
RittsREJrDelvillanoBCGovlWHerbermanRBKlugtLZuranskiVRJr. Initial clinical evaluation of immuno-radiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer1984; 33: 339–45.
3.
SteinbergWMGelfandRAndersonKK. Comparison of the sensitivity and specificity of CA 19-9 and carcino embryonic antigen assay in detecting cancer of the pancreas. Gastroenterology1986; 90: 343–9.
4.
PleskowDKBergerHJGyvesJAllenEMcLeanAPodolskyDK. Evaluation of serologic marker, CA 19-9 in the diagnosis of pancreatic cancer. Ann Int Med1989; 110: 704–9.
5.
Van-denBoschRPVan EijckCHMulderPGJeckalJ. Serum CA 19-9-a determination in management of pancreatic cancer. Hepatogastroenterology1996; 43: 710–13.
6.
BeniniLCavalliniGZordonD. A clinical evaluation of monoclonal (CA 19-9, CA 50, CA 12-5) and polyclonal (CEA, TP A) antibody defined antigens for the diagnosis of pancreatic cancer. Pancreas1998; 3: 61–6.
7.
HomaTTsuchiyaR. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan using CA 19-9 and elastase I or ultrasonography. Int J Pancreatol1991; 9: 919–24.
8.
ChenSB. Diagnostic value of serum CA 19-9 determination in digestive tract cancer [in Chinese]. Chung-Hua-Chung-Liv. Zhonghua Zhong Liu Za Zhi1990; 12: 58–60.
9.
HaglundCRobertsPJJalankoHKouselaD. Tumor marker CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol1992; 27: 169–74.
10.
SatakeKTakeochiT. Comparison of CA 19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas1994; 9: 720–4.
